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Introduction. To compare the diagnostic values of laboratory variables, to present evaluations of the diagnostic test for asymmetric
dimethyl arginine (ADMA), rheumatoid factor (RF), C-reactive protein (CRP), and DAS
28
index, and to define the effect of
untreated rheumatoid arthritis on endothelial function. In order to determine whether ADMA changes depending on the disease
evolution, ADMAwas used as an indicator for endothelial dysfunction.Methods. Using an ELISA technology of DLD-Diagnostika-
GMBH for the detection of ADMA, the samples of serum and urine have been examined in 70 participants (35 RA who were not
treated, 35 healthy controls). RF was defined with the test for agglutination (Latex RF test) in the same participants. Results. Out of
35 examined patients with RA, RF appeared in 17 patients (sensitivity of the test, 51.42%). In 20 of the 35 examined patients with
RA, we found the presence of ADMA (sensitivity of the test, 57.14%). Anti-CCP antibody was present in 24 examined patients with
RA (sensitivity of the test, 68.57%). Conclusion. ADMA has equal or very similar sensitivity and specificity to RF in untreated RA
(sensitivity of 57.14% versus 48.57%, specificity of 88.57% versus 91.42%) in the detection of asymptomatic endothelial dysfunction
in untreated RA.
1. Introduction
Rheumatoid arthritis (RA) is a disease which encompasses
up to 1% of the whole population and is associated with an
increased risk for onset and development of cardiovascular
diseases (CVD). Data show that those patients have 30–60%
increased risk for CVD in comparison with patients with
osteoarthritis [1]. Patients with RA with disease duration
of more than 10 years have increased risk of myocardial
infarction [2] and more expressed process of atherogenesis
because of the chronic systemic inflammation.
Circulatory markers of the systemic inflammation sig-
nificantly increase the risk of cardiovascular morbidity and
mortality in this group of patients, far more than traditional
risk factors such as smoking, diabetes, and hypertension [3–
9]. There are numerous analogues between RA and athero-
clerosis, including macrophages, T-cell activation, unbalance
between T helper 1 and T helper 2 lymphocytse, increased
level of circulatory reactants of the acute phase and adhesion
molecules, increased production of endothelins, oxidative
radicals and increased neoangiogenesis in early but as well
in long-lasting RA. Endothelial dysfunction occurs in the
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absence of manifest CVD and is not connected with tradi-
tional atherosclerotic risk factors [10–12].
1.1. Biomarkers for Assessment of Endothelial Dysfunction.
Few classes of measurable serum proteins are used in the
assessment of cardiovascular system:
(1) biomarkers of myocyte injury: troponin I, troponin
T, creatine kinase isoenzymes (CK-MB), and myo-
globin;
(2) biomarkers ofmyocyte stress: natriuretic peptides—A
type (ANP), B type (BNP), adrenomedullin, midre-
gional proadrenomedullin, and ST2;
(3) biomarkers of remodeling: (MMPs) 1,2,7,8,9; (TIMPs)
1,2; procollagen type III;
(4) Biomarkers of endothelial dysfunction: P-Selectin,
scCAM-1, semi-carbazide sensitive amine oxidase
(SSAO), vascular adhesion protein 1 (VAP-1), ADMA
and SDMA, von Willebrandt factor, L-arginine, and
nitric oxide metabolites (NO
𝑥
);
(5) biomarkers of inflammation: CRP, IL-1, IL-6, IL-10,
TNF-𝛼;
(6) neurohormonal biomarkers: endothelin 1 (ET-1), big-
endothelin 1 (Big ET-1).
Of the whole markers of the endothelial dysfunction, dim-
ethyl derivatives of the amino acid L-Arginine incite greatest
attention. There are two stereoisomer shapes of L-arginine,
symmetric and asymmetric derivatives.
1.2. Symmetric Dimethyl Arginine (SDMA). This is a methy-
lated derivative of amino acid Arginine. It is eliminated from
the body exclusively with renal excretion. Therefore, SDMA
plasma concentration is tightly connected with the renal
function. Determination of the plasma level of SDMA is
important for assessment of renal failure [13–15].
1.3. Asymmetric Dimethyl Arginine (ADMA). Synonyms (2S-
2-amino 5-[(aminodimethylaminomethylen) amino]) pen-
tanoic acid; N,N-Dimethylarginine; at C
8
H
18
N
4
O
2
and natu-
ral chemical matter are normally present in plasma. They are
metabolic products of continual processes of protein mod-
ification in cytoplasm in all human cells, tightly connected
with essential amino acid L-arginine. ADMA interferes with
L-arginine in the production of nitric monoxide (NO) which
has key role in the normal endothelial function. NO is
synthesised in endothelial cells with the enzyme endothe-
lial nitric oxide synthetase (NOS) (EC 1.14.13.39). It has 3
isoenzyme forms: endothelial (eNOS), neural (nNOS), and
in macrophages and in other immune cells (iNOS) involved
in immune response. NO is activated through haemoglobin.
Physiologic substrate, that is, precursor for NOS in this
enzymatic process is L-arginine which is converted into NO
andL-citrulline.NOS is inhibited by the endogenous arginine
metaboliteADMA.Plasma level ofADMA is increased inRA.
ADMA is synthesised with protein methylation, that is,
with posttranslational modification of arginine residues, in
different proteins, mostly in cell nucleus. Methylation of the
arginine residues is catalyzed by the group of enzymes called
protein arginine N-methyl transferases (PRMTs). Basically,
when proteins are proteolysed, free-methyl arginines are
liberated.
The reaction is catalysed by the enzymes S-adenosyl-
methionine (SAM) as well as (protein methylases type I
and II) (PRMTs). They transfer one or more methyl groups
from donor S-adenosyl-methionine to L-arginine with pro-
teins or polypeptides. Both subtypes PRMTs have ability
to methylate monomethyl arginine (MMA), so that type 1
asymmetrically dimethylates arginine and creates ADMA,
while type 2 catalyses symmetric dimethylation of arginine
and creates SDMA. ADMA and MMA have the ability to
inhibit NOS but not SDMA. After synthesis, ADMAmigrates
to extracellular space and plasma. Human being generates
about 300𝜇mol/daily (about 60mg/daily) of ADMA. Of
this quantity, about 50𝜇mol/daily is excreted in the urine.
The elimination of ADMA is through urinary excretion
after previous metabolization of the enzyme dimethylargi-
nine dimethylaminohydrolase, dymethylargininasa, DDAH.
There are 2 isoforms of DDAH
1
andDDAH
2
andwhich differ
in the cell distribution. DDAH
1
predominates in tissues that
contain neural NOS, while DDAH
2
is predominant in tissues
with expression of endothelial NOS [16].Themain aim of this
enzyme is degradation ofmethyl arginines, especially ADMA
andMMA.The degradation of 80% of the daily production of
ADMA is catalysed by DDAH [17].
2. Defining the Problem
RA is characterisedwith inflammation, key component in the
onset and development of atherosclerosis.The inflammation,
through activation of endothelial cells and through increase
of the expression of leukocyte adhesion molecules, promotes
proatherosclerotic environment.The endothelial dysfunction
is an early preclinical marker for the onset of atherosclerosis
and is often present in RA.
The endothelial dysfunction is closely connected with the
inflammation, and therapeutic reduction of the inflamma-
tion leads towards its improvement. The assessment of the
endothelial function is a useful tool in the identification and
monitoring of the cardiovascular risk in patients with RA.
Due to the fact that increased cardiovascular mortality is
associated with RA, except the control of the activity of the
disease, it is necessary to takemeasures, activities, and actions
in the early detection and prevention of the cardiovascular
risk.
The systemic inflammation presented in RA is char-
acterised with the activation of the vascular endothelium,
leukocytes, and platelets. Incapability, that is, vasodilatation
dysfunction of the arterioles known as endothelial dysfunc-
tion, is the first phase for the appearance of the atherosclerotic
damage. The endothelial dysfunction is localised on the level
of arterioles, <100 𝜇m in diameter, where the effect of NO
is manifested, but it is forecondition for the appearance
of atherosclerosis as ubiquitous disease of the middle-sized
muscle arteries such as coronary, carotide, basilar, vertebral,
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and also with big calibre: aorta, iliacal, and arteries of the
lower extremities.
The endothelial dysfunction is connected with several
possible processes.
(1) Changes in the formation of the extracellular matrix
and synthesis of the components of the basal mem-
brane.
(2) Changes in the cell synthesis and liberation of vasoac-
tive matters.
(3) Changes in the processes of coagulation, platelet
aggregation, and athession.
(4) Proliferative processes of the smoothmuscle cells and
fibroblasts.
(5) Dysbalance between endothelial relaxing and con-
tracting substances.
2.1. Suggested Mechanisms for the Increased Plasma Level of
ADMA inRA. (1) Decreased activity ofDDAH, a key enzyme
which regulates ADMAdegradation but not SDMA, is able to
increase the ADMA plasma level. ADMA is liberated during
degradation of proteins that contain methylated arginine
residues [18]. NOS is inhibited by ADMA.
(2) Activity of DDAH is reversibly proportional with
the presence of tumour necrotic factor alpha (TNF𝛼) [19–
22], NOS, and S-nytrosylation. Because in RA quantities of
TNF𝛼 oxygene radicals and 3-nitrotirosine are increased,
it is hypothesised that the selective increase of ADMA
plasma level in RA is the result of decreased DDAH activ-
ity in plasma. The chronical presence of proinflammatory
cytokines as IL-1a, IL-1b, IL-6 and TNF𝛼, and CRP from the
synovial tissue directly influences the systemic endothelial
dysfunction. Treatman with anti-TNF𝛼 in the 12th week
significantly improves the endothelial vasodilatation of the
brachial artery [23].
(3) Second possibility is that oxidative stress connected
with RA can increase formation of ADMA through increased
expression of protein arginine 1N-methyltransferase [24].
Substrates of these argine 1Nmethyltransferases are proteins
with side-chain arginine guanidine groups.
(4) Third possibility is that the inflammatory synovia in
RA is with increased proliferation and potent apoptosis of the
vascular endothelial cells [25].The cultivated endothelial cells
liberatemore ADMA than SDMA [26]. Increased endothelial
cell turnover in RA with successive liberation of ADMA
during catabolism of the proteins results in increased level of
ADMA in RA.
(5) Hypoxia in the inflamed synovia in RA decreases ex-
pression of DDAH [27]. Decreased DDAH activity increases
the concentration of ADMA.
(6) The tendency towards insulin resistance is noticed in
patients with RA, but positive association between plasma
level of ADMA and insulin resistance is noticed in healthy
individuals with different levels of insuline sensitivity [28].
This phenomenon is hypothetically connectedwith increased
liberation of ADMA.
(7) The role of homocysteine as a risk factor for CVD is
through the inhibitory effect of the regulatory production of
DDAH in the body. It is quickly regulated with vitamin B
supplements. High endothelial LDL cholesterol increases the
level of ADMAwhich in return inhibits the production ofNO
necessary for vasodilatation.
Increased level of ADMA is found in patients with homo-
cysteinemia [29], coronary disease [30], peripheral arterial
occlussive diseases [31], pulmonary hypertension [32], and as
a result of smoking [33] and diabetes [34]. Common thing for
all these conditions is that ADMA is endogenous inhibitor
of NOS. New perspective and cross-sectional studies indi-
cate that the increased level of ADMA is a risk factor for
cardiovascular conditions and lethal outcome [35]. ADMA is
significant as a new cardiovascular risk factor in RA.
ADMA activity is low in serum and is increased in
the presence of endothelial dysfunction due to the presence
of inflammation in RA. It is a very sensitive indicator of
endothelial damage in comparison to the invasive and non-
invasive functional measurements. The use of ADMA is
a relatively simple, cheap, fast, and nonivasive method in
detection of the early stadium of diesease and followup
of the endothelial disorder. Therefore, its presence would
be quantified with the level of inflammation in RA which
correlates with the disease activity.
3. Aims of the Study
(1) To determine initial presence of ADMA in patients
with RA.
(2) To examine the connection between plasma ADMA
level and the activity of the disease with its charac-
teristics. To investigate whether circulatory factors of
NOmetabolism, ADMA, reflect on clinical character-
istics of RA.
(3) To determine whether mediators of the inflammatory
reactions in RA influence microvascular, endothelial
NO metabolism.
(4) To confirm the statement that the appearance of
the subclinical atherosclerosis in RA is connected
with the accumulation of the endogenous inhibitor
of nitric monoxide synthetase and plasma level of
ADMA.
(5) To determine correlations among plasma level of
ADMA with the duration of disease, index of the
strength of the disease (DAS-28), age of the patient
and duration of disease, and evolution of disease be-
fore the beginning of treatment.
(6) To determine correlations between plasma level of
ADMA and reactants of the acute phase.
(7) To determine whether seropositivity in RA influence
plasma level of ADMA.
(8) To determine whether there is correlation between
ADMA and anticyclic citrullinated peptide antibod-
ies (anti-CCP
2
) from the second generation.
(9) On the base of the values of examined parameters
that should be followedup and their correlation to
determine whether biomarker would be the most
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adequate not only for early detection of endothelial
damage but also for the best clinical, prognostic, and
economic end-effect.
4. Material and Methods
In the patients examined for this study, the diagnosis of the
disease was established on the basis of revised diagnostic
criteria for the classification of rheumatoid arthritis, sug-
gested in 1987 by the American Association for Rheumatism
(ARA) [36]. In order for a patient to be diagnosed with
rheumatoid arthritis, he or she must fulfill at least four out
of seven criteria. Criteria from one to four are present for
at least six weeks. The study involved 35 patients (female 27,
male 8) suffering from RA and 35 healthy subjects (female 17,
male 18) from the control group. Their average age was 55.57
years (±5.68) (39–65 years) in the group with RA and 45.1
years (±11.37) (29–65 years) in the control group.The average
duration of the disease in months from the beginning was
42.86 (±44.12) in the interval of 5–157 months. None of the
patients had been previously treatedwith oral corticosteroids.
The rest of the patients refused to use other medicines before
taking the examinations; Table 1.
4.1. Including Criteria. In this study, patients with RA, age 18–
65, newly diagnosed and not treated would be included.
4.2. Excluding Criteria. From the study all patients/individu-
als with diseases or conditions that could directly or indirectly
influence changes of results (diagnosed in the course of the
study would be excluded), like the following:
(1) patients with past history for disease of the spleen,
liverdamage, renal, hematological, cardiological, neu-
rological, and lung injuries, autoimmune diseases,
AIDA, and age <18 years;
(2) patients suffering from conditions that affect lipid
profile, such as smoking, diabetes, hypothyreosis,
Cushing’s syndrome, and obesity (body mass index
>30, with family history of dyslipidemia);
(3) patients with acute infections, malignant diseases,
febrile conditions;
(4) patients previously treated with some basic drug for
RA, including CSs and NSAIDs;
(5) patients with hypertension, uric gastritis, urinary
infections, systemic lupus erythematosus, mixed con-
nective tissue disease, vasculitis, systemic scleroise,
primary and secondary Raunaud phenomena, per-
iferal vascular diseases, and congenital CVD;
(6) patients treated with antihypertensive, antidiabetic,
and cardiologic therapy, drugs for decrease of the lipid
profile, oral contraceptives, estrogens, progesteron,
and tocopherol (vitamin E);
(7) patients previously blood transfused;
(8) patients in whom in 0-time would be found increased
level of glycose, degradational products, like serum
Table 1: Patients characteristics examined in the study.
RA no. 35
Value (M± SD)
Control healthy
group no. 35
Value (M± SD)
Male/female relation 8/27 18/17
Middle average age (years) 55.57 (±5.68)(39–65)
45.10 (±11.37)
(29–65)
Middle duration (time) of
disease (month)
42.86 (±44.12)
(5–157)
0.00 (±0.00)
(0.00-0.00)
Previous therapy with oral
corticosteroids
(no. of patients)
0 0
Previus therapy with
methotrexate
(no. of patients)
0 0
and urine creatinin, serum urea, hypertension, and
changes in hematological parameters or enzymatic
status.
All patients took part in this study voluntarily, so the ethical
criterion was not breached during our work.
4.3. Clinical Evaluation of Disease Activity. Changes in the
evolution of disease, that is, clinical improvements, would be
assessed through suitable indexes of activity (clinical param-
eters) (Disease Activity Score-DAS
28
) [37–40]. The index
uses mathematical formula in order to get unique composite
quantitative score composed of palpatory painfully sensitive
joints (maximal score 28), swollen joints (maximal score 28),
Westergren ESR, and patients global evaluation for disease
activity (0–100mm Visual Analogue Scale-VAS).
DAS
28
index ranges from 0 to 10, and score below 3.2
qualifies the disease as low active.
DAS
28
: 0.56 0.56 √0–28 palpatory painfully sensitive
joints + 0.28 √0–28, swallen joints +0.70 (log
𝑛
ESR) + 0.014
(global estimation of the patient for disease activity: VAS 0–
100).
4.4. Biochemical Laboratory Examination. For a clinical as-
sessment of the basic disease, the following laboratory var-
iables needed to be measured: haemogram and differential
haemoalysis, reactors of acute phase, anti-CCP
2
antibody,
C-reactive protein (CRP), rheumatic factor (RF), alkaline
phosphatase (AP), aspartate aminotransferase (AST), ala-
nine aminotransferase (ALT), creatinine kinase (CK), lactate
dehydrogenase (LDH), urea and creatinine in serum, and
Asymmetric dimetil L-arginine (ADMA).
4.5. Determination of the Activity of Asymetric Dimethyl L-
Arginin (ADMA): ELISA Method (DLD Diagnostics, GMBH)
Enzyme Immunoassay. For quantitative determination of
the endogenous Asymetric dimethyl L-arginine (ADMA) in
serum or plasma.
Principle: ADMA is adhered in solid phase on microtiter
plate. ADMA standard, samples, and positive control are
preacylated, in combination with rabbit anti-N-acyl-ADMA,
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Table 2: Distribution of ADMA, reactant of acute phase and other laboratory variables in patients with RA and healthy control group.
Ra not treated group
no. 35
Value (M± SD)
RAsero−
no. 18
Value (M± SD)
RAsero+
no. 17
Value (M± SD)
Control healthy group
no. 35
Value (M± SD)
Positive/negative Positive/negative Positive/negative Positive/negative
ADMA
+>0.75 𝜇mol/L
20/15
08.10 (±0.75)
(0–210)
7/11
11.22 (±0.72)
(0–110)
13/4
13.16 (±0.40)
(0–210)
4/31
11.75 (±0.22)
(55.20–105.33)
Sedimentation
+≥16
25/10
46.43 (±41.79)
(1.0–110)
11/7
40.70 (±37.63)
(1.0–110)
13/4
51.38 (±37.37)
(1.0–110)
3/32
7.31 (±7.10)
(1.0–31)
Anti CCP2 ≥1.26
24/11
1.82 (±0.71)
(0.91–2.0)
12/6
1.45 (±0.48)
(0.91–1.5)
11/6
1.76 (±0.80)
(0.91–1.9)
1/34
0.84 (±0.09)
(0.90–1.27)
RF
+≥8 IU/mL
18/17
335.09 (±515.11)
(0.00–512)
0/18
0.00 (±0.00)
(0.00-0.00)
17/0
601.67 (±622.68)
(32–1024)
3/32
11.69 (±40.69)
(0.00–128)
DAS28 +≥3.2
29/6
5.81 (±1.44)
(1.76–6.01)
14/4
5.30 (±1.55)
(1.72–6.01)
16/1
4.01 (±1.29)
(1.39–5.81)
0/35
0.00 (±0.00)
(0.00-0.00)
incubated for 15–20 h at 2–8∘C. After that they are washed,
and second antibody is added, anti-rabbit IgG, conjugated
with peroxidase. After 1−hour incubation a room temperature
they are washed. In order to achieve colour, tetramethylben-
zidine is added as a substrate solution (TMV). After 20–30
minutes incubation, it is stopped with adding sulphur acid.
The absorbtion is read on 450 nm on automatical microtitar
reader. With the standard figureis determined ADMA con-
centration. Basically, the quantity of antibodies adhered in
the solid phase of ADMA is reversely proportional to the
concentration of ADMA in the samples.
Refererent values: ADMA in serum0.4–0.75micromol/L.
Determination of the C-reactive protein (CRP) and rheu-
matoid factor (RF) with test for agglutination (Latex CRP
test). (BioSystems S. A. Reagens & Instruments Costa Brava
30, Barcelona, Spain).
Refererent values are +>6mg/L CRP in serum; +>8mg/L
for RF in serum.
Determination of anticyclic cetrullinated peptide anti-
bodies (anti-CCP
2
) with semiquantitative/qualitative ELISA
technique, based on the detection of IgG autoantibodies in
human serum or plasma, directed towards synthetic cyclic
citrulated peptides (CCPs) that contain modified arginine
residues.TheDIA-STAT anti-CCP (Axis-ShieldDiagnostics).
Refererent values are +>1.26 positive values for anti-CCP
in serum.
Determination of the erythrocyte sedimentation rate
(ESR) with quantitative method of Westergren with normal
values for males is 7-8mm, for woman 11–16mm.
5. Statistical Analysis
Predictive values for positive and negative results and accu-
racy of examinedmarks were definedwith the test of sensitiv-
ity and specificity. Analysis of the structure of numeric series
is made by the measures of the central tendency (average)
and measures of dispersion (standard deviation); analysis
of the structure of the attributive statistical series is made
by coefficients of correlations and proportions; analysis of
correlation between numeric statistical series is made by
Pearson’s coefficient of correlation-𝑝; analysis of correlation
between attributive statistical series is made by Pearson’s
𝜒
2-test. To test the significance of differences between two
arithmetical medians that is, proportions Student’s 𝑡-test is
used and aWilcoxon-matched test for independentexamples.
To test the significance of differences among three or more
arithmetical medians, analysis of variance (ANOVA) is used.
A 𝑃 value between 0.05 and 0.1 was taken as statistically
significant. The results would be statistically processed with
the following statistical methods and shown with statistical
package Statististica 7.0.
6. Results
Of all the examined patients with RA, ADMA is detected
in 20 patients (57,14%), about acute phase reactant, RF was
detected in 17 patients (48.57%), anti-CCP antibody in 23
patients (65.71%), CRP in 14 patients (40%), and sedimen-
tation in 27 patients (77.14%). In the healthy control group,
RF was present in 2 patients (5.71%). DAS
28
is present in
28 patients with RA (80%). Among 18 RF negative patients,
7 patients (38.88%) were ADMA positive. Among 17 RF-
positive RA patients, presence of ADMA was found in 13
(76.47%) patients. In the healthy control group, 4 patients
(11.42%) were ADMA positive; Table 2.
Diagnostic value of ADMA in patients with rheumatoid
arthritis (RA) sensitivity, specificity, and predictive values of
the positive and negative tests as well as their precision is
shown in Table 3.
ADMA has equal.or very similar sensitivity and speci-
ficity from RF in untreated RA (sensitivity 57.14% versus
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Table 3: Diagnostic values of ADMA, and other labaratory variables in patients with RA.
Sensitivity
%
Specificity
%
Predictive values for
the positive test
%
Predictive values for
the negative test
%
Accuracy
%
ADMA
RA no. 35 57.14 88.57 83.33 32.60 72.85
ADMA
RA− no. 18 38.88 88.57 63.63 26.19 71.69
ADMA
RA+ no. 17 76.47 88.57 76.47 11.42 84.61
Sedimentation
RA no. 35 71.42 91.42 89.28 23.80 81.42
Sedimentation
RA− no. 18 61.11 91.42 78.57 17.94 81.13
Sedimentation
RA+ no. 17 76.47 91.42 81.25 11.11 86.53
Anti CCP antibody
RA no. 35 68.57 97.14 96 24.44 82.85
Anti CCP antibody
RA− no. 18 66.66 97.14 92.30 15 86.79
Anti CCP antibody
RA+ no. 17 64.70 97.14 91.66 15 86.53
RF
RA No35 51.42 91.42 85.70 34.69 71.42
RF
RA− no. 18
0 91.42 0 36 60.37
RF
RA+ no. 17 100 91.42 85 0 94.23
DAS28
RA no. 35 82.85 100 100 14.63 91.42
DAS28
RA− no. 18 77.77 100 100 10.25 92.45
DAS28
RA+ no. 17 94.11 100 100 2.77 98.07
48.57%, specificity 88.57% versus 94.28%) in the detection of
RA.
6.1. Association between Asymmetric Dimethylarginine and
Disease Activity Score (DAS
28
) in Patients with Rheumatoid
Arthritis. Among 35 patients with RA, DAS
28
was replaced
in 29 patients (82.85%). In 17 seropositive RF patients,
replacement of DAS
28
was detected in 16 patients (94.11%).
Of these 16 DAS
28
patients, 9 were ADMA positive (56.25%).
Among 18 seronegative RF patients, replacement of DAS
28
was found in 14 patients (77.77%). Of these 14 DAS
28
patients,
5 were ADMA positive (35.71%), and their M±SD was 6.03 ±
0.21.
Seropositive RF patients have bigger ADMA value of
circumference than seronegative RF patients (13,16 (±0,40)
versus 11,22 (±0,72) and bigger DAS
28
index of intensity of
disease (6.03 ± 0.21) versus (3.75 ± 0.85). Between these two
groups of ADMA), there is no statistical connection (𝑃 =
0.74); see Table 2.
There was no statistical connection using the Wilcoxon-
matched test between the DAS
28
index in RF seropositive and
seronegative patients (𝑃 = 0.48) and between two groups
of DAS
28
, ADMA positive patients and seronegative patients
(𝑃 = 0.33).
(1) Statistical relation was found using the Wilcoxon-
matched test betweenADMA inRA and age, duration
of disease, RF, CRP, sedimentation, and morning
rigid, in the same group for 𝑃 < 0.05 (ADMA vs age
𝑃 = 0.000; ADMA vs duration of disease, 𝑃 = 0.000;
ADMA vs RF, 𝑃 = 0, 015; ADMA vs CRP 𝑃 = 0, 030;
ADMAvsSedimentation, 𝑃 = 0, 000).
(2) There was no statistical connection using the
Wilcoxon-matched test between ADMA in RA and
healthy control group for 𝑃 < 0.05 (𝑃 = 0.064),
Figure 1.
7. Discussion
Not only the ever growing prevalence of the CVD in RA,
but also the use of drugs that change the disease activity
in disease treatment contributes to the deepening of the
investigations towards finding easy, cheap, and practical
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ADMA in RF seropositive patients
ADMA in RF seronegative patients
ADMA in RA untreated patients
ADMA in healthy control group
Mean
Mean ± SD
−1 0 1 2 3 4 5
ADMA in RF seronegative patients with DAS
28
ADMA in RF seropositive patients with DAS
28
Mean ± 1.69 ∗ SD
Figure 1: Distribution of asymmetric dimethylarginine (ADMA) in serum (0.4–0.75micromol/L).
screening method, in order to detect the early stadium of
disease of the endothelium.
There are several biomarkers as indicators for endothe-
lial dysfunction such as endothelial vasoactive substances,
leukocyte athesion substances, proinflammatory cytokines,
prostaglandins, reactants of the acute phase, hormones,
enzymes. Everyone has its own importance in the functioning
of the blood vessels. ADMA is the unique substance onwhich
the multifunctional role of NO depends, but as endogenous
antiatherogenic molecule. Direct effect on the autoregulation
of the normal myogenic activity and vasomotion (potent
vasodilator effect), athession (inhibition of the platelet aggre-
gation, inhibition of athession of the monocytes and leuko-
cytes in normal vascular endothelium), proliferation (inhibi-
tion of proliferation of vascular smooth muscle cells), with
basic aim achievement and maintenance of trans musculare,
capillary pressure. ADMAhas indirect effect on the process of
atherosclerosis: it decreases vascular liberation of superoxide
radicals involved in the inflammatory and cytokine processes
and inhibition of LDL oxydation.
Until recently ADMA was detected with liquid chro-
matography, making it complex, inaccessible, technologically
dependent, and expensive. With the introduction of ELISA
method in the detection of ADMA, determination becomes
more accessible and more practical.
ADMA plasma level is increased in RA without CVD or
presence of risk factors. There is strong association between
ADMA and anticyclic citrulated peptide antibodies (anti-
CCP
2
) from the second generation in early RA without
cardiovascular risk factors as a result of the activity of disease
and inflammatory activation. Our case shows that there
is association between ADMA and anticitrulated peptide
antibodies (anti-CCP
2
) in early RA [41–44]. ADMA plasma
level shows dependence on duration and disease evolution.
Seropositivity in RA has influence on ADMA plasma level.
It shows in our example that patients with presence of RF
with DAS
28
index of disease have higher ADMA induction
than seronegative patients with DAS
28
. Statistical connection
between disease duration and presence of ADMA show
that untreated RA works an endothelium as one of visceral
appearance of the disease.
Endothelial dysfunction has been suggested as an early
event in the atherogenic process and as a novel predictor of
CHD events; more recent longitudinal studies in the CHD
arena provide some support for this proposition [45]. Several
studies employing various “direct” measures of vascular
function such as pulse wave analysis [46], flow-mediated
vasodilation [47], and venous occlusion plethysmography
[48] confirm endothelial dysfunction in RA patients. Where
examined, such dysfunction has been linked to systemic
inflammatory markers. Vaudo and associates [49] have pro-
vided more recent evidence for endothelial dysfunction in
young to middle-aged patients with low disease activity (dis-
ease activity score), DAS ≤3.2, and noted a strong association
to average CRP levels. This finding agrees with the earlier
observation of an early excess risk of vascular events in RA
patients. Elevated LDL cholesterol also was an independent
correlate to impaired vascular function in RA patients in the
latter study. Other more recent studies also show impaired
vessel stiffness with the technique of pulse wave velocity
[50], and we have shown impaired forearm microvascular
function using laser Doppler imaging in patients with RA
in parallel with a greater systemic inflammatory response
[51].
More recent longitudinal studies report improved en-
dothelial function after antitumor necrosis factor (TNF)-𝛼
therapy [52, 53], but this benefit seems to be transient and
linked to the pattern of change in systemic inflammatory
8 Arthritis
markers on TNF blockade. Treatment with disease-modify-
ing antirheumatic drugs (DMARDs) also improves endothe-
lial function in patients with RA [48], so the mechanism
employed to achieve inflammatory controlmay not be crucial
to the improvement in endothelial function.
8. Conclusion
ADMA has high sensitivity in the detection of asymptomatic
endothelial dysfunction in untreated RA. The practical sig-
nificance of the determination of ADMA plasma level in
everyday clinical practice results form the fact that the doctor,
according to the results of its concentration could change
not only diagnostic but also therapeutic tactics. With the
followup of the dynamics of changes of concentration of
ADMA, and they could judge for the nature and development
of the disease and its outcome. These possibilities make
determination of ADMA plasma level practically important
for on-time information to the doctor, considering disease
nature and its severity.
Disclosure
Trial registration number is A210895/12.
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